CSS LLC’s BioMarin Pharmaceuticals BMRN Stock Holding History

CSS LLC’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-3,500	Closed	-$312K	–	527
2017 Q4	$312K	Hold	3,500	–	–	0.02%	417
2017 Q3	$326K	Hold	3,500	–	–	0.02%	427
2017 Q2	$318K	Buy	+3,500	New	+$318K	0.02%	431
2017 Q1	–	Sell	-4,100	Closed	-$340K	–	640
2016 Q4	$340K	Hold	4,100	–	–	0.02%	416
2016 Q3	$379K	Hold	4,100	–	–	0.02%	429
2016 Q2	$319K	Hold	4,100	–	–	0.02%	476
2016 Q1	$338K	Buy	4,100 +100	+3%	+$8.14K	0.02%	419
2015 Q4	$419K	Hold	4,000	–	–	0.02%	401
2015 Q3	$421K	Buy	+4,000	New	+$534K	0.02%	431

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CSS LLC's BMRN Position: Q1 2026 in Review

CSS LLC reduced its BioMarin Pharmaceuticals (BMRN) stake by 25% in Q1 2026, selling an estimated $303K and leaving 15,980 shares worth $903K. The position accounts for 0.04% of the portfolio, ranked #369.

CSS LLC first reported a position in BMRN in Q3 2016 and has held it in 10 quarters since. The position peaked at $1.3M in Q3 2025. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

CSS LLC held 15,980 shares of BioMarin Pharmaceuticals worth $903K as of Q1 2026.
CSS LLC sold 5,200 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $303K.
BioMarin Pharmaceuticals made up 0.04% of CSS LLC's portfolio in Q1 2026, its #369 holding.
CSS LLC first reported a position in BioMarin Pharmaceuticals in Q3 2016 and has held it in 10 quarters since.
CSS LLC's BioMarin Pharmaceuticals position peaked at $1.3M in Q3 2025.
555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on CSS LLC's 13F filing for Q1 2026, filed 15 May 2026.